Core Insights - Arcutis Biotherapeutics has launched ZORYVE® (roflumilast) topical foam, the first new drug approved for seborrheic dermatitis in over two decades, which is now available in pharmacies [1][2] - ZORYVE foam is a steroid-free treatment option that provides rapid disease clearance and significant reduction in itch for patients aged 9 and older [1][6] - The product is expected to address unmet needs in the treatment of seborrheic dermatitis, a condition affecting over 10 million people in the U.S. [1][2] Product Details - ZORYVE foam is indicated for the treatment of seborrheic dermatitis in patients aged 9 years and older [6] - The foam is designed for once-daily application and is suitable for use on various skin and hair types, as well as across the full spectrum of disease severity [2] - Clinical trials showed that over 50% of subjects achieved complete clearance, and 75% reached IGA treatment success at 8 weeks, with over 40% achieving success as early as 2 weeks [2] Market Positioning - The launch of ZORYVE foam marks Arcutis' second commercial product in the U.S., with strong reimbursement support from major pharmacy benefit managers [2] - The company aims to establish ZORYVE as a new standard of care for seborrheic dermatitis, filling a significant gap in treatment options [2][3] Patient Support Programs - Arcutis has introduced the ZORYVE Direct Program to assist patients in accessing their prescribed medication, including a savings card program to reduce out-of-pocket costs for eligible patients [3] - The company also offers the Arcutis Cares™ patient assistance program for uninsured or underinsured patients [3] Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on developing innovative treatments for immune-mediated dermatological diseases [5] - The company has a growing portfolio that includes two FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions [5]

Individual patient response data highlight 91.5% of individuals treated with roflumilast cream had a measurable improvement in Eczema Area and Severity Index (EASI) in just 4 weeks85% achieved measurable improvement by Week 1 (the earliest timepoint measured)Data presented at the 2024 Winter Clinical Dermatology Conference - Hawaii WESTLAKE VILLAGE, Calif., Jan. 14, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meanin ...

New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE foam than an identical vehicleZORYVE foam provided rapid and significant improvement in quality of life scores in patients 17 years and olderData presented at the 2024 Winter Clinical Dermatology Conference - Hawaii WESTLAKE VILLAGE, Calif., Jan. 14, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDA ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Eric McIntyre - Head of Investor Relations Frank Watanabe - President and Chief Executive Officer Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer John Smither - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Seamus Fernandez - Guggenheim Securities Vikram Purohit - Morgan Stanley Uy Ear - Mizuho Chris Shibutani - Goldma ...

3rd Quarter 2023 Financial Results & Business Update Legal Disclaimers This presentation and the accompanying oral presentation candidates, and our ability to serve those markets; our statements, whether written or oral, that may be made from time contain “forward-looking” statements that are based on our commercialization, marketing and manufacturing capabilities and to time, whether as a result of new information, future management’s beliefs and assumptions and on information strategy; current and future ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form10-Q 91361 (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or O ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Eric McIntyre - Head-Investor Relations Frank Watanabe - President & Chief Executive Officer Ayisha Jeter - Interim-Chief Commercial Officer Patrick Burnett - Chief Medical Officer Scott Burrows - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Louise Chen - Cantor S ...

2nd Quarter 2023 Financial Results & Business Update Legal Disclaimers This presentation and the accompanying oral presentation candidates, and our ability to serve those markets; our to time, whether as a result of new information, future contain “forward-looking” statements that are based on our commercialization, marketing and manufacturing capabilities and developments or otherwise. management’s beliefs and assumptions and on information strategy; current and future agreements with third parties in curr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form10-Q 91361 (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Eric McIntyre - Head of Investor Relations Frank Watanabe - President & Chief Executive Officer Patrick Burnett - Chief Medical Officer Ken Lock - Chief Commercial Officer Scott Burrows - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Seamus Fernandez - Guggenheim Securities Uy Ear - Mizuho Louise Chen - Cantor Greg Fraser - Truist Securities Sean Kim ...